Akebia Therapeutics Cash Flow - Annual (NASDAQ:AKBA)

Add to My Stocks
$8.28 $0.05 (0.6%) AKBA stock closing price Sep 21, 2018 (Closing)

For analyzing any company like Akebia Therapeutics from an investment perspective, its important to check the cash flow statement. While its important to look at the Akebia Therapeutics debt position, the cash flow statement becomes equally important because public companies use accrual accounting. For example, if a company sells a product which gets counted as Akebia Therapeutics revenue but does not convert to cash because it does not receive payment in the same quarter, it affects the cash position for that period. The cash flow statement is essetial while conducting the Akebia Therapeutics cash flow analysis and can be used to measure the operating performance of Akebia Therapeutics compared to various industry peers like BSTC stock and VRCA stock. AKBA decrease in investments stood at a value of $-177.26M for the latest year 2017.

View details of Akebia Therapeutics cash flows for latest & last 10 financial years
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec201720162015201420132012
Net Income Cash Flow
-76.91M-135.74M-60.71M-37.03M-13.16M-8.19M
Depreciation Depletion Amortization Cash-Flow1.22M----1.67M
Net Increase (Decrease) in Assets Liabilities7.24M186.73M2.94M3.22M1.92M-0.8M
Cash From (used in) Discontinued Operations------
Other Adjustments Net12.28M6.13M4.71M6.01M-0.85M-
Net Cash from (used by) Operating Activities
-56.15M57.9M-52.4M-27.48M-11.33M-7.21M
Increase (Decrease) in Prop Plant And Equipment-1.62M-2.66M-0.41M-0.22M-0.01M-
Acquisition Disposition of Subsidiaires------
Increase (Decrease) in Investments-175.63M15.36M-13.27M-65.12M-11.4M1.36M
Other Cash Inflow (Outflow) from Investment Activities------
Net Cash from (used by) Investment Activities
-177.26M12.7M-13.68M-65.35M-11.42M1.36M
Issuance (Purchase) of Equity Shares116.24M66.96M83.1M104.16M43.74M2.5M
Issuance (Repayment) of Debt Securities-0.01M-0.02M-0.01M---
Increase (Decrease) in Bank & Other Borrowings------
Payment of Dividends & Other Cash Distributions------
Other Cash from (used by) Financing Activities-----1.41M-0.02M
Net Cash from (used by) Financing Activities
116.24M66.94M83.09M104.4M42.33M2.47M
Effect of Exchange Rate Changes on Cash------
Net Change in Cash & Cash Equivalents
-117.17M137.55M16.99M11.56M19.57M-3.37M
Cash & Equivalents at Beginning of Year187.33M49.77M32.78M21.21M1.64M5.01M
Cash & Equivalents at Year End70.15M187.33M49.77M32.78M21.21M1.64M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

The statement of cash flows comprises of cash flow from financing, cash flow from operations and cash flow from investing activities. All the three can have an impact on the stock price. The Akebia Therapeutics stock price history and Akebia Therapeutics stock comparison chart inevitably reflect its cash flow situation.

  • Akebia Therapeutics has cash of $70.15M on hand. A healthy amount of cash on hand is necessary for any company. Cash has an opportunity cost associated with it, and too much cash in bank may mean that the firm has no or limited growth plans. Hence its important to track the Net Change in Cash and Cash Equivalents along with the Akebia Therapeutics stock price.
  • Cash Flow from operating activities: Akebia Therapeutics reported a negative operating cash flow of $-56.15M for 2017 and has seen a decrease from the previous year. Operating cash flow comes from main business activities. Investors look for positive cash flow from recurring operating activities.
  • Cash Flow from investment activities: This includes buying/selling of land and equipment, acquisitions and mergers, sell-off, investment in other companies like buying bonds, stocks etc., and was $-177.26M for AKBA in last 2017 report.
  • Cash flow from financing activities shows the flow of cash between Akebia Therapeutics and its owners and creditors and was $116.24M for 2017. Financing activities allow a company to raise capital, and repay bondholders.

Key Financial Ratios For Akebia Therapeutics Cash Flow

FCF margin
0.18